Of note, the wide confidence intervals reported in a cohort study reported by Chia et al on 117 patients with stage I HER-2+ breast cancer, the HR+ subgroup showed a higher RFS at 10 years (77.5% versus 68.3%) [8]. Here, ERBB2 is linked to breast carcinoma.